Tag
This newsletter covers two major tech stories: a biotech company's first human trial of 'reprogramming' cells to reverse aging, and the growing field of interoception research. It also notes SpaceX's record-breaking IPO.
A biotech company has dosed its first volunteer in a clinical trial for an experimental glaucoma treatment that uses cellular reprogramming to reverse age-related damage, part of a broader trend toward rejuvenation therapies.